• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The clinical application of the serum pepsinogen I and II levels as a mass screening method for gastric cancer.

作者信息

Miki K, Ichinose M, Kakei N, Yahagi N, Matsushima M, Tsukada S, Ishihama S, Shimizu Y, Suzuki T, Kurokawa K

机构信息

First Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.

出版信息

Adv Exp Med Biol. 1995;362:139-43. doi: 10.1007/978-1-4615-1871-6_17.

DOI:10.1007/978-1-4615-1871-6_17
PMID:8540312
Abstract
摘要

相似文献

1
The clinical application of the serum pepsinogen I and II levels as a mass screening method for gastric cancer.血清胃蛋白酶原I和II水平作为胃癌大规模筛查方法的临床应用。
Adv Exp Med Biol. 1995;362:139-43. doi: 10.1007/978-1-4615-1871-6_17.
2
A minute gastric cancer detected by a new screening method using serum pepsinogen I and II.一种通过使用血清胃蛋白酶原I和II的新筛查方法检测出的微小胃癌。
Adv Exp Med Biol. 1995;362:145-8. doi: 10.1007/978-1-4615-1871-6_18.
3
The usefulness of gastric mass screening using serum pepsinogen levels compared with photofluorography.与荧光摄影相比，利用血清胃蛋白酶原水平进行胃癌群体筛查的实用性。
Hiroshima J Med Sci. 1997 Jun;46(2):81-6.
4
The association of smoking and drinking habits with serum pepsinogens.吸烟和饮酒习惯与血清胃蛋白酶原的关联。
Int J Epidemiol. 1995 Apr;24(2):346-53. doi: 10.1093/ije/24.2.346.
5
Correlation of ratio of serum pepsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects.日本人群血清胃蛋白酶原I与II的比值与胃癌及腺瘤患病率的相关性
Am J Gastroenterol. 1998 Jul;93(7):1090-6. doi: 10.1111/j.1572-0241.1998.00335.x.
6
Evaluation of cutoff levels for screening of gastric cancer using serum pepsinogens and distributions of levels of serum pepsinogen I, II and of PG I/PG II ratios in a gastric cancer case-control study.在一项胃癌病例对照研究中，利用血清胃蛋白酶原筛查胃癌的临界值评估以及血清胃蛋白酶原I、II水平和PG I/PG II比值的分布情况。
J Epidemiol. 1997 Sep;7(3):143-51. doi: 10.2188/jea.7.143.
7
A novel tree-structured analysis for non-invasive diagnosis of gastric adenocarcinoma.一种用于胃腺癌非侵入性诊断的新型树状结构分析。
Anticancer Res. 1995 Nov-Dec;15(6B):2739-43.
8
Serum pepsinogen values as possible markers for evaluating the possibility of peptic ulcer recurrence under H2-blocker half-dose maintenance therapy.血清胃蛋白酶原水平作为评估H2受体阻滞剂半量维持治疗下消化性溃疡复发可能性的潜在标志物。
Adv Exp Med Biol. 1995;362:131-7. doi: 10.1007/978-1-4615-1871-6_16.
9
Two cases of early colorectal cancer associated with gastric adenoma detected by serum pepsinogen screening method.通过血清胃蛋白酶原筛查法检测出的两例与胃腺瘤相关的早期结直肠癌病例。
Adv Exp Med Biol. 1995;362:149-54. doi: 10.1007/978-1-4615-1871-6_19.
10
Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer.血清胃蛋白酶原I和II水平在胃癌大规模筛查中的临床应用
Jpn J Cancer Res. 1993 Oct;84(10):1086-90. doi: 10.1111/j.1349-7006.1993.tb02805.x.

引用本文的文献

1
Comparison of Gastric Cancer Risk Classifications Using Conventional and New Pepsinogen Criteria.使用传统和新的胃蛋白酶原标准对胃癌风险分类进行比较。
Gastroenterol Res Pract. 2023 May 30;2023:7646536. doi: 10.1155/2023/7646536. eCollection 2023.
2
A Global Perspective on Gastric Cancer Screening: Which Concepts Are Feasible, and When?胃癌筛查的全球视角：哪些概念可行，何时可行？
Cancers (Basel). 2023 Jan 21;15(3):664. doi: 10.3390/cancers15030664.
3
Cancer/testis antigen, Kita-Kyushu lung cancer antigen-1 and ABCD stratification for diagnosing gastric cancers.
癌症/睾丸抗原、北九州肺癌抗原 1 和 ABCD 分层在胃癌诊断中的应用。
World J Gastroenterol. 2020 Jan 28;26(4):424-432. doi: 10.3748/wjg.v26.i4.424.
4
Immunohistochemical Analysis of LGR5 and TROY Expression in Gastric Carcinogenesis Demonstrates an Inverse Trend.LGR5和TROY在胃癌发生过程中表达的免疫组化分析显示出相反的趋势。
Iran Biomed J. 2019 Mar;23(2):107-20. doi: 10.29252/.23.2.107. Epub 2018 Dec 3.
5
Predicting the Development of Gastric Neoplasms in a Healthcare Cohort by Combining Antibodies and Serum Pepsinogen: A 5-Year Longitudinal Study.通过联合抗体和血清胃蛋白酶原预测医疗队列中胃肿瘤的发生：一项5年纵向研究
Gastroenterol Res Pract. 2018 Jul 24;2018:8796165. doi: 10.1155/2018/8796165. eCollection 2018.
6
Screening Biomarker as an Alternative to Endoscopy for the Detection of Early Gastric Cancer: The Combination of Serum Trefoil Factor Family 3 and Pepsinogen.筛查生物标志物作为内镜检查的替代方法用于早期胃癌检测：血清三叶因子家族3与胃蛋白酶原的联合应用
Gastroenterol Res Pract. 2018 May 9;2018:1024074. doi: 10.1155/2018/1024074. eCollection 2018.
7
Premalignant Gastric Lesions in Patients Included in National Colorectal Cancer Screening.纳入国家结直肠癌筛查的患者中的癌前胃病变
Radiol Oncol. 2017 Dec 7;52(1):7-13. doi: 10.1515/raon-2017-0054. eCollection 2018 Mar.
8
Randomized controlled trial comparing gastric cancer screening by gastrointestinal X-ray with serology for Helicobacter pylori and pepsinogens followed by gastrointestinal endoscopy.比较胃肠道X线胃癌筛查与幽门螺杆菌和胃蛋白酶原血清学检测随后进行胃肠道内镜检查的随机对照试验。
Gastric Cancer. 2015 Jul;18(3):605-11. doi: 10.1007/s10120-014-0408-5. Epub 2014 Aug 13.
9
Pepsinogen II can be a potential surrogate marker of morphological changes in corpus before and after H. pylori eradication.胃蛋白酶原 II 可作为 H. pylori 根除前后胃体形态变化的潜在替代标志物。
Biomed Res Int. 2014;2014:481607. doi: 10.1155/2014/481607. Epub 2014 Jun 17.
10
A survey and evaluation of population-based screening for gastric cancer.基于人群的胃癌筛查的调查和评估。
Cancer Biol Med. 2013 Jun;10(2):72-80. doi: 10.7497/j.issn.2095-3941.2013.02.002.